Foghorn reports FY2022 net loss $108.9M; cash $345.8M; pipeline data expected H1 2023

Foghorn Therapeutics Inc.

Net loss $108.9M for FY2022; R&D expenses $105.6M, collaboration revenue $19.2M.
Cash, equivalents and marketable securities $345.8M as of Dec 31, 2022; runway into H2 2025.
Phase 1 data for FHD-286 in mUM expected H1 2023; AML/MDS clinical hold update H1 2023.
Phase 1 data for FHD-609 in synovial sarcoma expected mid-2023.
Newly disclosed selective EP300 degrader targeting CBP mutant cancers; potential for >100K patients/year.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Foghorn Therapeutics Inc.: Amended and restated bylaws to address universal proxy rules under Rule 14a-19 (effective 2023-03-07).

Change: bylaw amendment
Effective: 2023-03-07

Exact text from the filing

On March 7, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards and a periodic review of the Company's bylaws, the Company's board of directors approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became immediately effective.

View on SEC.gov

Browse all governance changes →

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-007139

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.